SarinaAnnePiha-PaulMD

Oncology • Houston, TX

Hematologic Oncology

Associate Professor, Phase I Fellowship Program Director

Join to view full profile

Dr. Piha-Paul is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Piha-Paul's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone(713) 563-1055
Is this information wrong?

Education & Training

University of Texas MD Anderson Cancer CenterFellowship, Hematology/Oncology, 2006 - 2009
Baylor College of MedicineResidency, Internal Medicine, 2002 - 2006
Louisiana State University School of Medicine in New OrleansClass of 2002

Certifications & Licensure

OK State Medical License 2020 - 2021
TX State Medical License 2008 - 2021

Clinical Trials

BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 01O'Neil, B.,Whittenberger, B.P.,Miller, C.,Sohal, D.,Safran, H.,Crosswell, H.,Gore, I.,Lukas, J.,Singh, J.,Peguero, J.,Nadauld, L.,Lakhani, N.,Piha-Paul, S.,Schmidt, W.G.,Chae, Y.
LDE225 for Patients With PTCH1 or SMO Mutated Tumors Start of enrollment: 2014 Feb 01Sohal, D.,Richards, D.A.,Peguero, J.,Nadauld, L.,Johnson, M.L.,Levine, R.,Piha-Paul, S.,Powell, S.
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 01Novartis Pharmaceuticals
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors Start of enrollment: 2013 Oct 01Shah, M.A.,Fu, S.,So-Rosillo, R.,Wheler, J.,Tai, E.,Piha-Paul, S.A.,Yu, P.P.,Zinner, R.G.,Janku, F.,Tsimberidou, A.M.,Schneider, B.,Naing, A.,Tagawa, S.T.,Falchook, G.S.,Hong, D.S.,Popa, E.C.,Subbiah, V.,...
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT Start of enrollment: 2013 Aug 01Groves, M.D.,Dhillon, N.,Santala, R.G.,Shimkus, B.J.,Thompson, M.A.,Cohn, A.L.,Hermann, R.C.,Larson, T.G.,Spigel, D.R.,Boyd, T.E.,Chawla, S.P.,Nikolinakos, P.G.,Taylor, M.H.,Blau, S.,Palchak, D.L.,Spitz, ...
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 01Beck, J.M.,Wade, J.L.,Demetri, G.D.,Sohal, D.P.,Savin, M.A.,Buscema, J.,Dhillon, N.,Thambi, P.M.,Hurwitz, H.,Yardley, D.A.,Richards, D.A.,Nikolinakos, P.G.,Vaena, D.A.,Grilley-Olson, J.E.,Schwartzberg, L....
Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab Start of enrollment: 2012 Mar 01Piha-Paul, S.
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2010 Jun 01Piha-Paul, S.
Clinical Response to Chemotherapy With Fluoro-L-Thymidine With Positron Emission Tomography (FLT-PET) Start of enrollment: 2009 Apr 01Piha-Paul, S.
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy Start of enrollment: 2008 Jan 01Kurzrock, R.,Piha-Paul, S.
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Sarina Piha-Paul
Safety of ABM-1310 Monotherapy in Patients With Advanced Solid Tumors Sarina A Piha-Paul, M.D.
Study of AMV564 in Subjects With Advanced Solid Tumors Patrick Chun, MD
Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer Sarina A. Piha-Paul, MD
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Ingmar Bruns, MD PhD
Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation Sarina Piha-Paul, MD
Join now to see all

Publications & Presentations

PubMed

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
Andrew W Hahn, Omar Alhalabi, Pavlos Msaouel, Funda Meric-Bernstam, Aung Naing, Eric Jonasch, Sarina Anne Piha-Paul, David S. Hong, Shubham Pant, Timothy A. Yap, Erick...> ;ESMO open. 2020 Nov 1
Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors.
Alexej Ballhausen, Jennifer J. Wheler, Daniel D. Karp, Sarina Anne Piha-Paul, Siqing Fu, Shubham Pant, Apostolia Maria Tsimberidou, David S. Hong, Vivek Subbiah, Veron...> ;Clinical Cancer Research. 2020 Oct 28
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.
Mendoza, T., Sheshadri, A., Altan, M., Hess, K., George, G., Stephen, B., Castillo, L., Rodriguez, E., Gong, J., Peterson, C., Ahnert, J. R., Fu, S., Piha-Paul, S. A.,...> ;Journal for immunotherapy of cancer. 2020 Oct 25
Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated...
Mukhtar, E., Worroll, D., Galletti, G., Schuster, S., Piha-Paul, S. A., Giannakakou, P.> ;Cancer drug resistance (Alhambra, Calif.). 2020 Oct 17
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Janku, F., Park, H., Call, S. G., Madwani, K., Oki, Y., Subbiah, V., Hong, D. S., Naing, A., Velez-Bravo, V. M., Barnes, T. G., Hagemeister, F. B., Falchook, G. S., Ka...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Oct 16
Efficacy and Safety of Pembrolizumab for the Treatment of Advanced Biliary Cancer: Results From the KEYNOTE-158 and KEYNOTE-028 Studies
Sarina Anne Piha-Paul, Do Youn Oh, Makoto Ueno, David Malka, Hyun Cheol Chung, Adnan Nagrial, Robin Kate Kelley, Willeke Ros, Antoine Italiano, Kazuhiko Nakagawa, Hope...> ;International Journal of Cancer. 2020 Oct 15
Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-Refractory Advanced Solid Tumors
Filip Janku, Halle H. Zhang, Abdul Mohammad Pezeshki, Sanjay Goel, Ravi Murthy, Andrea Wang-Gillam, Dale R. Shepard, Thorunn Helgason, Tyler Masters, David S. Hong, Sa...> ;Clinical Cancer Research. 2020 Oct 12
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional In...
Dumbrava, E. E., Balaji, K., Raghav, K., Hess, K., Javle, M., Blum-Murphy, M., Ajani, J., Kopetz, S., Broaddus, R., Routbort, M., Demirhan, M., Zheng, X., Pant, S., Ts...> ;JCO precision oncology. 2020 Sep 15
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multico...
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., Italiano, A., Kao, ...> ;The Lancet. Oncology. 2020 Sep 14
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in ...
Naing, A., Eder, J. P., Piha-Paul, S. A., Gimmi, C., Hussey, E., Zhang, S., Hildebrand, V., Hosagrahara, V., Habermehl, C., Moisan, J., Papadopoulos, K. P.> ;Journal for immunotherapy of cancer. 2020 Aug 28
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Janice M. Mehnert, Emily K. Bergsland, Bert H. O'Neil, Armando Santoro, Jan H.M. Schellens, Roger B. Cohen, Toshihiko Doi, Patrick A. Ott, Michael J. Pishvaian, Igor P...> ;Cancer. 2020 Jul 1
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination tr...
Subbiah, V., Dumbrava, E. I., Jiang, Y., Thein, K. Z., Naing, A., Hong, D. S., Fu, S., Piha-Paul, S. A., Tsimberidou, A. M., Janku, F., Meric-Bernstam, F., Kurzrock, R...> ;Experimental hematology & oncology. 2020 Apr 28
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies.
Taylor, M. H., Alva, A. S., Larson, T., Szpakowski, S., Purkaystha, D., Amin, A., Karpiak, L., Piha-Paul, S. A.> ;Oncotarget. 2020 Apr 16
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Sarina Anne Piha-Paul, Christine L. Hann, Christopher A. French, Sophie Cousin, Irene Brana, P. A. Cassier, Victor Moreno, Johann S. de Bono, Sara Duckworth Harward, G...> ;JNCI Cancer Spectrum. 2020 Apr 1
Phase 2 study of pembrolizumab in patients with advanced rare cancers.
Naing, A., Meric-Bernstam, F., Stephen, B., Karp, D. D., Hajjar, J., Ahnert, J. R., Piha-Paul, S. A., Colen, R. R., Jimenez, C., Raghav, K. P., Ferrarotto, R., Tu, S.,...> ;Journal for immunotherapy of cancer. 2020 Mar 20
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Gerald Steven Falchook, Razelle Kurzrock, Hesham M. Amin, Wenyuan Xiong, Siqing Fu, Sarina Anne Piha-Paul, Filip Janku, Ghazaleh Eskandari, Daniel V.T. Catenacci, Manf...> ;Clinical Cancer Research. 2020 Mar 15
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Gerald Steven Falchook, Seth Rosen, Patricia LoRusso, Justin M. Watts, Shilpa Gupta, Catherine C. Coombs, Moshe Talpaz, Razelle Kurzrock, Monica M. Mita, Ryan D. Cassa...> ;Clinical Cancer Research. 2020 Mar 15
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
Lillian M. Smyth, Sarina Anne Piha-Paul, Helen Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos...> ;Cancer Discovery. 2020 Feb 1
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
Strosberg, J., Mizuno, N., Doi, T., Grande, E., Delord, J., Shapira-Frommer, R., Bergsland, E., Shah, M., Fakih, M., Takahashi, S., Piha-Paul, S. A., O'Neil, B., Thoma...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jan 26
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H., Kao, S., Miller, W. H., Delord, J., Gao, B., Planchard, D., Gottfried, M., Zer, A., Jalal, S. I., P...> ;Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Dec 25
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib
Gary A. Ulaner, Cristina Saura, Sarina Anne Piha-Paul, Ingrid A. Mayer, David I. Quinn, Komal Jhaveri, Ben Stone, Seta Shahin, Grace Mann, Melanie E. Dujka, Richard Br...> ;Clinical Cancer Research. 2019 Dec 15
A Deep Learning Framework for Predicting Response to Therapy in Cancer.
Theodore Sakellaropoulos, Konstantinos Vougas, Sonali Narang, Filippos Koinis, Athanassios Kotsinas, Alexander Polyzos, Tyler J. Moss, Sarina Anne Piha-Paul, Hua Zhou,...> ;Cell Reports. 2019 Dec 10
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population.
George, G. C., Mendoza, T. R., Iwuanyanwu, E. C., Manandhar, M., Afshar, S. F., Piha-Paul, S. A., Tsimberidou, A., Naing, A., Cleeland, C. S., Hong, D. S.> ;Investigational new drugs. 2019 Nov 26
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Piha-Paul, S. A., Taylor, M. H., Spitz, D., Schwartzberg, L., Beck, J. T., Bauer, T. M., Meric-Bernstam, F., Purkayastha, D., Karpiak, L., Szpakowski, S., Braiteh, F.> ;Oncotarget. 2019 Nov 20
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., Piha-Paul, S. A., Doi...> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Nov 5
Join now to see all

Lectures

A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/re...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplifi...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all